Back to results
US 2012/0238468 A1Published application
Methods for diagnosing irritable bowel syndrome
AssigneeAak Patent B.V.
InventorsLambertus Tuk, Willem Meindert De Vos, Mirjana Rajilic-Stojanovic
Life of this patent
Estimating the term…
Abstract
The present invention discloses a method for diagnosing Irritable Bowel Syndrome (IBS) in a test sample by determining the level of several bacterial taxa in the test sample, comparing this level with the levels of those bacterial taxa in a control sample, and relating the level to a diagnosis of IBS. Additionally, the present invention provides a method for treatment of IBS based on said diagnosis. Also, the invention provides a method for subtyping IBS in a test sample.
Claims22
A method for diagnosing and/or subtyping Irritable Bowel Syndrome (IBS) in a test sample, said method comprising the steps of:
- a) determining the levels of two or more bacteria which are present in statistically significantly different levels between IBS subjects and healthy subjects, said bacteria being selected from IBS-decreased bacteria and IBS-increased bacteria, said IBS-decreased bacteria being selected from bacteria belonging to the supertaxon Bacteroidetes, selected from the taxa Prevotella melaninogenica et rel., Prevotella oxalis et rel., Uncultured Bacteroidetes, Tannerella et rel., Parabacteroides distasonis et rel., Allistipes et rel., Bacteroides plebeius et rel., Bacteroides splachnicus et rel., or to the supertaxon Clostridium cluster IV, selected from the taxa Subdoligranulum variabile et rel., Faecalibacterium prausnitzii et rel., Oscillospira guillermondii et rel., Sporobacter termitidis et rel., Ruminococcus callidus et rel., Eubacterium siraeum et rel., Anaerotruncus colihominis et rel., Clostridium cellulosi et rel., Clostridium leptum et rel., Ruminococcus bromii et rel., or to the supertaxon Clostridium cluster IX, said bacteria belonging to the taxon Phascolarctobacterium faecium et rel.;
- or to the supertaxon Clostridium cluster XVI, said bacteria belonging to the taxon Eubacterium biforme et rel.;
- or to the supertaxon Clostridium cluster XVII, said bacteria belonging to the taxon Catenibacterium mitsuokai et rel.;
- or to the supertaxon Proteobacteria, said bacteria belonging to the taxon Xanthomonadaceae;
- or to the supertaxon Uncultured Clostridiales, selected from the taxa Uncultured Clostridiales I and Uncultured Clostridiales II;
- or to the supertaxon Uncultured Mollicutes, said bacteria belonging to the taxon Uncultured Mollicutes, and said IBS-increased bacteria being selected from bacteria belonging to the supertaxon Clostridium cluster XIVa, selected from the taxa Dorea formicigenerans et rel., Ruminococcus obeum et rel., Clostridium nexile et rel., Clostridium symbiosum et rel., Outgrouping Clostridium cluster XIVa, Ruminococcus lactaris et rel., Lachnospira pectinoschiza et rel.;
- in a test sample;
- b) Comparing said level of said two or more IBS-decreased and/or IBS-increased bacteria in said test sample to a level of said two or more IBS-decreased and/or IBS-increased bacteria in a control sample;
- and
- c1) relating a decreased level of said IBS-decreased bacteria and/or an increased level of said IBS-increased bacteria in the test sample compared to the control sample to a diagnosis that the test sample is from a subject suffering from Irritable Bowel Syndrome;
- and/or
- c2) relating an increased level of said IBS-increased bacteria or a decreased level of said IBS-decreased bacteria in the test sample compared to the control sample to a diagnosis of whether the test sample is from a subject suffering from IBS-A, IBS-C, or IBS-D.
9 more elements
A method for diagnosing and/or subtyping Irritable Bowel Syndrome (IBS) in a test sample, said method comprising the steps of:
- i) providing a test sample;
- ii) determining the level of at least three nucleic acids capable of hybridising to at least three nucleic acid sequences selected from the nucleic acid sequences of SEQ ID Nos:1-100, or derivatives or fragments thereof deviating by at most 2 nucleotides, and complements, reverse, and reverse complements thereof, under stringent hybridization conditions, in said test sample;
- ii) comparing the level of said at least three nucleic acids from said test sample to the level of said at least three nucleic acids from a control sample;
- and
- iiia) relating the level of said at least three nucleic acids from said test sample to a diagnosis of whether the test sample is from a subject suffering from Irritable Bowel Syndrome;
- and/or
- iiib) relating the level of said at least three nucleic acids from said test sample to a diagnosis of whether the test sample is from a subject suffering from IBS-A, IBS-C, or IBS-D.
4 more elements
A method for diagnosing and/or subtyping Irritable Bowel Syndrome (IBS) in a test sample, said method comprising the steps of:
- i) providing a test sample;
- ii) determining the level of at least three nucleic acids capable of hybridising to 16S rRNA nucleic acid sequences hybridizing to the complementary strand of any of the nucleic acid sequences SEQ ID NO.:1-100 or fragments of said 16S rRNA nucleic acid sequences hybridizing to the complementary strand of any of the nucleic acid sequences SEQ ID NO.:1-100, and complements, reverse, and reverse complements thereof, under stringent hybridization conditions, in said test sample;
- ii) comparing the level of said at least three nucleic acids from said test sample to the level of said at least three nucleic acids from a control sample;
- and
- iiia) relating the level of said at least three nucleic acids from said test sample to a diagnosis of whether the test sample is from a subject suffering from Irritable Bowel Syndrome;
- and/or
- iiib) relating the level of said at least three nucleic acids from said test sample to a diagnosis of whether the test sample is from a subject suffering from IBS-A, IBS-C, or IBS-D.
4 more elements
An array for diagnosing IBS and/or subtyping IBS-A, IBS-C, or IBS-D, said array comprising at least two nucleic acid sequences having the nucleic acid sequence of SEQ ID NOs:
- 1-100, or derivatives or fragments thereof deviating by at most 2 nucleotides, or complements, reverse, and reverse complements thereof.
Dependencies are inferred from the claim text.